WO2023134145A1 - 一种替沃扎尼关键中间体的制备方法 - Google Patents

一种替沃扎尼关键中间体的制备方法 Download PDF

Info

Publication number
WO2023134145A1
WO2023134145A1 PCT/CN2022/108014 CN2022108014W WO2023134145A1 WO 2023134145 A1 WO2023134145 A1 WO 2023134145A1 CN 2022108014 W CN2022108014 W CN 2022108014W WO 2023134145 A1 WO2023134145 A1 WO 2023134145A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
reaction
inert solvent
chloro
Prior art date
Application number
PCT/CN2022/108014
Other languages
English (en)
French (fr)
Inventor
池王胄
殷保胜
孙东艳
谢敏敏
Original Assignee
上海天慈生物谷生物工程有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海天慈生物谷生物工程有限公司 filed Critical 上海天慈生物谷生物工程有限公司
Publication of WO2023134145A1 publication Critical patent/WO2023134145A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
    • C07C209/32—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups
    • C07C209/36—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups by reduction of nitro groups bound to carbon atoms of six-membered aromatic rings in presence of hydrogen-containing gases and a catalyst
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/88—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/247—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention belongs to the field of medicinal chemistry, and in particular relates to a preparation method of a key intermediate of Tivozanib.
  • Tivozanib the chemical name is N-[2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl -3-isoxazolyl) urea, is a potent and selective VEGFR inhibitor, when acting on VEGFR1/2/3, IC50 is 0.21nM/0.16nM/0Chemicalbook.24nM, also inhibits PDGFR and c- Kit has weak activity on FGFR-1, Flt3, c-MetEGFR and IGF-1R.
  • the TIVO-3 study is a controlled, multicenter, open-label phase III clinical trial that randomly selected 350 patients with highly refractory metastatic renal cell carcinoma who had previously received 2 regimens (including VEGF-TKI therapy). Failed, received tivozanib hydrochloride capsules or sorafenib in a 1:1 ratio (crossed arms were not allowed).
  • Treatment with Tivozanib (Tivozanib Hydrochloride Capsules) is generally well tolerated and has a better safety profile.
  • the most common grade 3 or 4 adverse event in both groups was hypertension.
  • the most common adverse events associated with treatment with Tivozanib were hypertension (38%), diarrhea (33%), fatigue (29%), and decreased appetite (27%).
  • tivozanib is a very effective drug for the treatment of renal cell carcinoma.
  • the compound of formula I is a key intermediate that is difficult to bypass in the synthesis of tivozanib, so the preparation method of the compound of formula I is particularly important for the synthesis of tivozanib.
  • WO2021/150792 discloses the following routes:
  • the amino group in the raw material is an electron-donating group, and the amino hydrogen is more active, the subsequent docking reaction is more difficult and there are more impurities, and the reaction needs to use a strong base such as potassium tert-butoxide, and the reaction conditions are relatively harsh, which is not conducive to industrial production.
  • the invention provides a preparation formula I compound 2-chloro-4-((6,7-dimethoxy ylquinolin-4-yl)oxy)-aniline method.
  • the present invention provides a method for preparing a compound of formula I, comprising the steps of:
  • the base is an inorganic base, and the base is selected from: sodium hydroxide, potassium hydroxide, sodium hydrogen, sodium amide, potassium carbonate, sodium carbonate, or a combination thereof, Preferred are sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, or combinations thereof.
  • the inert solvent is selected from: N,N-dimethylformamide, N,N-dimethylacetamide, acetone, dimethyl sulfoxide, acetonitrile, tetrahydrofuran, or combination.
  • step s1) the molar ratio of the compound of formula VI to the compound of formula III is 1:0.8-2, preferably 1:0.9-1.6, more preferably 1:1-1.5 .
  • the reaction temperature is 60-80°C, preferably 50-70°C.
  • step s1) has one or more of the following features:
  • the temperature of the reaction is 40-80°C, preferably 60-80°C, preferably 50-70°C;
  • the reaction time is 0.5-5h, preferably 0.5-4h, more preferably 3-4h.
  • step s1) the inert solvent is acetone, and the base is potassium carbonate.
  • step s1) the inert solvent is N,N-dimethylformamide, and the base is sodium hydroxide.
  • step s2) the reducing agent is H 2 .
  • the catalyst in step s2), is selected from the group consisting of palladium carbon, Raney nickel, platinum dioxide, and the reducing agent is H 2 .
  • the reducing agent is a metal reagent, preferably iron powder, zinc powder, and stannous chloride.
  • the catalytic reagent is an acidic reagent, preferably hydrochloric acid, acetic acid, or ammonium chloride aqueous solution.
  • the combination of the acidic reagent and metal reagent is selected from: hydrochloric acid and iron powder, hydrochloric acid and zinc powder, acetic acid and iron powder, ammonium chloride aqueous solution and iron powder, hydrochloric acid and chlorine Stannous.
  • step s2) the reducing agent is H 2 , and the reaction is carried out in an autoclave under a certain pressure.
  • the inert solvent is selected from tetrahydrofuran, 2-methyltetrahydrofuran, ethanol, methanol, isopropanol, or combinations thereof.
  • step s2) the inert solvent is tetrahydrofuran, the catalyst is platinum dioxide, and the reducing agent is H 2 , and the reaction is carried out in an autoclave under a certain pressure.
  • step s2) the inert solvent is tetrahydrofuran, the catalyst is concentrated hydrochloric acid, and the reducing agent is stannous chloride.
  • step s2) has one or more of the following features:
  • the reaction temperature is 40-80°C, preferably 60-80°C, preferably 50-70°C, preferably 45-55°C;
  • the reaction time is 2-8h, preferably 3-6h, more preferably 3-4h.
  • the present invention provides a method for preparing a compound of formula II, wherein the method comprises the steps of:
  • the present invention provides a method for preparing a compound of formula I, wherein the method comprises the steps of:
  • the inventor After extensive and in-depth research, through a large number of screening and testing, the inventor has developed a compound that utilizes formula VI compound 4-chloro-6,7-dimethoxyquinoline and formula III compound 3-chloro-4-nitrophenol
  • the compound 2-chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)-nitrobenzene of the formula II is obtained through the Williamson ether-forming reaction, and then obtained by the reduction reaction of the formula
  • the present invention of the present invention provides a raw material that is easily available, low in cost, mild in reaction conditions, easy to purify the product, and high in yield, suitable for large-scale industrial production.
  • inert solvent refers to a reagent that does not react with the reaction substrate.
  • the present invention provides a preparation method of the compound of formula I, preferably, the method comprises the following steps
  • the second solvent is selected from: tetrahydrofuran, 2-methyltetrahydrofuran, ethanol, methanol, isopropanol, or a combination thereof;
  • the catalyst is selected from the group consisting of palladium carbon, Raney nickel, platinum dioxide;
  • the hydrogenation reaction under the catalysis of the catalyst should be carried out in an autoclave with a certain pressure
  • the solvent used is tetrahydrofuran and platinum dioxide is used as a catalyst.
  • the second solvent is also selected from tetrahydrofuran, 2-methyltetrahydrofuran, ethanol, methanol, isopropanol, or combinations thereof;
  • the combination of the acid reagent and metal reagent can be: hydrochloric acid and iron powder, hydrochloric acid and zinc powder, acetic acid and iron powder, ammonium chloride aqueous solution and iron powder, hydrochloric acid and stannous chloride.
  • the method also includes the steps of:
  • the strongly alkaline reagent includes but not limited to: sodium hydroxide, potassium hydroxide, sodium hydrogen, sodium amide, potassium carbonate, sodium carbonate, or a combination thereof;
  • the first solvent includes, but is not limited to: N,N-dimethylformamide, N,N-dimethylacetamide, acetone, dimethyl sulfoxide, acetonitrile, tetrahydrofuran, or combinations thereof;
  • the molar ratio of the compound of formula VI to the compound of formula III is 1:0.8-2, preferably 1:0.9-1.6, more preferably 1:1-1.5.
  • the temperature of the reaction is 40-80°C, preferably 60-80°C, preferably 50-70°C;
  • the reaction time is 0.5-5h, preferably 0.5-4h, more preferably 3-4h;
  • acetone is used as the reaction solvent
  • potassium carbonate is used as the alkaline reagent for the reaction.
  • N,N-dimethylformamide is used as the reaction solvent, and sodium hydroxide is used as the reaction base.
  • the present invention changes the reaction sequence in the technique through ingenious design, which greatly improves the efficiency and yield of Williamson's ether formation.
  • the present invention uses raw materials in the original process as much as possible, reducing the process development workload caused by replacing raw materials.
  • Step 1 of the present invention reduces the reaction sites due to the docking of nitro compounds, and improves the success rate of ether formation due to the electron-withdrawing characteristics of nitro, thereby improving the product purity.
  • the present invention has low cost and is suitable for large-scale industrial production.
  • 4-Chloro-6,7-dimethoxyquinoline can be purchased from Shanghai Huanfu Industrial Co., Ltd.
  • 3-Chloro-4-nitrophenol can be purchased from Shanghai Bi De Pharmaceutical Co., Ltd.
  • the raw materials of the present invention are easy to get, low in cost, mild in reaction conditions, easy to purify the product, and high in yield, and are suitable for industrialized large-scale production of the preparation compound 2-chloro-4-((6,7-dimethoxyquin The method of phen-4-yl)oxy)-aniline.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明提供了一种替沃扎尼关键中间体式Ⅰ化合物2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺的制备方法，以式Ⅵ化合物4-氯-6，7-二甲氧基喹啉和式III化合物3-氯-4-硝基苯酚为原料，经过威廉姆森成醚反应得到式Ⅱ化合物2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-硝基苯，再经还原反应得到式Ⅰ化合物2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺。该方法反应活性强，原料易得成本低廉，反应条件温和，产品易纯化，且收率高，适宜工业化大生产。

Description

一种替沃扎尼关键中间体的制备方法 技术领域
本发明属于药物化学领域，具体涉及一种替沃扎尼关键中间体的制备方法。
背景技术
Figure PCTCN2022108014-appb-000001
替沃扎尼，即化学名为N-[2-氯-4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(5-甲基-3-异恶唑基)脲，是一种有效的，选择性VEGFR抑制剂，作用于VEGFR1/2/3时，IC50分别为0.21nM/0.16nM/0Chemicalbook.24nM，也抑制PDGFR和c-Kit，作用于FGFR-1，Flt3，c-MetEGFR和IGF-1R活性较弱。由AVEO Oncology研发，FDA已于2021年3月批准了Tivozanib(Fotivda，盐酸替沃扎尼胶囊)的新药申请(NDA)，用于治疗复发/难治性肾细胞癌(RCC)。基于TIVO-3第三阶段试验的数据，与索拉非尼(Nexavar)相比，Tivozanib(盐酸替沃扎尼胶囊)在高复发/难治性转移性肾细胞癌患者的无进展生存期(PFS)有显著改善，且总生存期(OS)相似。结果表明，OS(总生存期)的最终危险比(HR)为0.97。此外，对Tivozanib(盐酸替沃扎尼胶囊)和索拉非尼的中位随访时间分别为38个月和40个月，盐酸替沃扎尼胶囊的中位总生存期为16.4个月，索拉非尼的中位总生存期为19.2个月。
TIVO-3研究是一项对照、多中心、开放标签的III期临床试验，随机选取350名高度难治性转移性肾细胞癌患者，这些患者之前接受2种方案(包括VEGF-TKI治疗)均失败，以1:1的比例接受盐酸替沃扎尼胶囊或索拉非尼治疗(不允许双臂交叉治疗)。
部分缓解：Tivozanib组18％，索拉非尼组8％
客观缓解率：Tivozanib组34％，索拉非尼组24％
与索拉非尼相比，Tivozanib(盐酸替沃扎尼胶囊)的治疗普遍耐受性良好，安全性也较好。接受Tivozanib(盐酸替沃扎尼胶囊)治疗的84％(n＝146)的患者和接受索拉非尼治疗的94％(n＝160)的患者报告了治疗相关不良事件(TRAEs)。两组患者中，最常见的3级或4级不良事件是高血压。与接受Tivozanib(盐酸替沃扎尼胶囊)治疗相关的、最常见的不良事件为高血压(38％)、腹泻(33％)、疲劳(29％)和食欲下降(27％)。
由上可见，替沃扎尼是一款非常有效的治疗肾细胞癌的治疗药物。
专利EP1559715所述的合成替沃扎尼方法如下：
Figure PCTCN2022108014-appb-000002
CN106967058中公开的合成替沃扎尼的方法，路线如下：
Figure PCTCN2022108014-appb-000003
文献Heterocycles,2016,vol.92,#10,p.1882-1887中披露的方法路线如下：
Figure PCTCN2022108014-appb-000004
比较以上三种方法可知，式Ⅰ化合物是合成替沃扎尼难以绕过的关键中间体，因而式Ⅰ化合物的制备方法，对于替沃扎尼的合成尤为重要。
WO2021/150792披露了如下路线：
Figure PCTCN2022108014-appb-000005
由于原料中氨基是给电子基团，且氨基氢较为活泼，后续对接反应比较困难杂质较多，并且反应中需要用到叔丁醇钾等强碱，反应条件较为苛刻，不利于工业化生产。
为了解决现在制备方法存在的问题，急需一种新的制备方法来代替现有方法。
发明内容
本发明提供了一种原料易得，成本低廉，反应条件温和，产品易纯化，且收率高，适宜工业化大生产的制备式I化合物2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺的方法。
本发明第一方面，提供一种式Ⅰ化合物的制备方法，包括步骤：
Figure PCTCN2022108014-appb-000006
s1)在惰性溶剂中，碱存在下，式Ⅲ化合物与式Ⅵ化合物发生反应，得到式Ⅱ化合物；所述反应的温度为40-80℃；
s2)在惰性溶剂中，催化剂存在下，式Ⅱ化合物与还原剂反应，得到式Ⅰ化合物。
在另一优选例中，步骤s1)中，所述碱为无机碱，且所述碱选自：氢氧化钠、氢氧化钾、钠氢、氨基钠、碳酸钾、碳酸钠，或其组合，优选地为氢氧化钠、氢氧化钾、碳酸钾、碳酸钠，或其组合。
在另一优选例中，步骤s1)中，惰性溶剂选自：N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、丙酮、二甲亚砜、乙腈、四氢呋喃，或其组合。
在另一优选例中，步骤s1)中，所述式Ⅵ化合物与式Ⅲ化合物的摩尔比为1:0.8-2，较佳地，1:0.9-1.6，更佳地，1:1-1.5。
在另一优选例中，步骤s1)中，所述反应的温度为60-80℃，较佳地，50-70℃。
在另一优选例中，步骤s1)具有以下一个或多个特征：
所述反应的温度为40-80℃,较佳地，60-80℃，较佳地，50-70℃；
所述反应的时间为0.5-5h，较佳地，0.5-4h，更佳地，3-4h。
在另一优选例中，步骤s1)中，惰性溶剂为丙酮，碱为碳酸钾。
在另一优选例中，步骤s1)中，惰性溶剂为N,N-二甲基甲酰胺，碱为氢氧化钠。
在另一优选例中，步骤s2)中，还原剂为H 2。
在另一优选例中，步骤s2)中，所述催化剂选自下组：钯碳、雷尼镍、二氧化铂，还原剂为H 2。
在另一优选例中，步骤s2)中，还原剂为金属试剂，优选地为铁粉、锌粉、氯化亚锡。
在另一优选例中，步骤s2)中，催化试剂为酸性试剂，优选地为盐酸、醋酸、氯化铵水溶液。
在另一优选例中，步骤s2)中，所述酸性试剂和金属试剂的组合选自：盐酸和铁粉、盐酸和锌粉、醋酸和铁粉、氯化铵水溶液和铁粉、盐酸和氯化亚锡。
在另一优选例中，步骤s2)中，还原剂为H 2，所述反应在高压釜中并带有一定压力下进行。
在另一优选例中，步骤s2)中，惰性溶剂选自：四氢呋喃、2-甲基四氢呋喃、乙醇、甲醇、异丙醇，或其组合。
在另一优选例中，步骤s2)中，惰性溶剂为四氢呋喃，催化剂为二氧化铂，还原剂为H 2，所述反应在高压釜中并带有一定压力下进行。
在另一优选例中，步骤s2)中，惰性溶剂为四氢呋喃，催化剂为浓盐酸，还原剂为氯化亚锡。
在另一优选例中，步骤s2)具有以下一个或多个特征：
所述反应的温度为40-80℃，较佳地，60-80℃，较佳地，50-70℃，较佳地，45-55℃；
所述反应的时间为2-8h，较佳地，3-6h，更佳地，3-4h。
本发明第二方面，提供一种式Ⅱ化合物的制备方法，其中，所述方法包括步骤：
Figure PCTCN2022108014-appb-000007
s1)在惰性溶剂中，碱存在下，式Ⅲ化合物与式Ⅵ化合物发生反应，得到式Ⅱ化合物。
本发明第三方面，提供一种式Ⅰ化合物的制备方法，其中，所述方法包括步骤：
Figure PCTCN2022108014-appb-000008
s2)在惰性溶剂中，催化剂存在下，式Ⅱ化合物与还原剂反应，得到式Ⅰ化合物。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
具体实施方式
发明人经过广泛而深入的研究，通过大量筛选和测试，开发了一种利用式Ⅵ化合物4-氯-6，7-二甲氧基喹啉和式III化合物3-氯-4-硝基苯酚为原料，经过威廉姆森成醚反应得到式Ⅱ化合物2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-硝基苯，再经还原反应得到式Ⅰ化合物2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺的新方法。本发明的本发明提供了一种原料易得，成本低廉，反应条件温和，产品易纯化，且收率高，适宜工业化大生产。
术语
本发明中，“惰性溶剂”是指不与反应底物发生反应的试剂。
式I化合物的制备方法
本发明提供了式I化合物的制备方法，优选地，所述方法包括如下步骤
Figure PCTCN2022108014-appb-000009
方法1
(ii)在第二溶剂中，在催化剂作用下，式Ⅱ化合物与氢气反应生成式Ⅰ化合物；
所述第二溶剂选自：四氢呋喃、2-甲基四氢呋喃、乙醇、甲醇、异丙醇，或其组合；
所述催化剂选自下组：钯碳、雷尼镍、二氧化铂；
所述催化剂催化下的氢化反应应当在高压釜中并带有一定压力下进行；
优选地，所使用的溶剂为四氢呋喃，二氧化铂作为催化剂。
方法2
(ii’)在第二溶剂中，使用金属试剂和酸性试剂的组合物，与式Ⅱ化合物反应生成式Ⅰ化合物；
所述第二溶剂同样选自四氢呋喃、2-甲基四氢呋喃、乙醇、甲醇、异丙醇，或其组合；
所述酸性试剂和金属试剂的组合可以为：盐酸和铁粉、盐酸和锌粉、醋酸和铁粉、氯化铵水溶液和铁粉、盐酸和氯化亚锡。
优选地，所述方法还包括步骤：
Figure PCTCN2022108014-appb-000010
(i)在第一溶剂中,在强碱性试剂作用下,式Ⅲ化合物与式Ⅵ化合物发生威廉姆森成醚反应，得到式Ⅱ化合物；
其中所述强碱性试剂包括但不限于：氢氧化钠、氢氧化钾、钠氢、氨基钠、碳酸钾、碳酸钠，或其组合；
所述第一溶剂包括但不限于：N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、丙酮、二甲亚砜、乙腈、四氢呋喃，或其组合；
所述式Ⅵ化合物与式Ⅲ化合物的摩尔比为1:0.8-2，较佳地，1:0.9-1.6，更佳地，1:1-1.5。
所述威廉姆森成醚反应具有以下一个或多个特征：
所述反应的温度为40-80℃,较佳地，60-80℃，较佳地，50-70℃；
所述反应的时间为0.5-5h，较佳地，0.5-4h，更佳地，3-4h；
优选地，使用丙酮作为反应溶剂，碳酸钾作为反应用碱性试剂。
优选地，采用N,N-二甲基甲酰胺作为反应溶剂，氢氧化钠作为反应用碱。
本发明的主要优点包括：
(1)本发明通过巧妙的设计更改了工艺中反应顺序，极大的提高了威廉姆 森成醚的效率和收率。
(2)本发明尽可能的使用原有工艺中原料，减少了更换原料导致的工艺开发工作量。
(3)本发明步骤一由于对接的是硝基化合物，减少了反应位点，而且由于硝基的吸电子特性，提高了成醚成功率，进而提高了产物纯度。
(4)本发明成本低适宜工业化大生产。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数是重量百分比和重量份数。
以下实施例中所用的实验材料和试剂如无特别说明均可从市售渠道获得。
试剂
4-氯-6，7-二甲氧基喹啉 可购自上海环孚实业有限公司
3-氯-4-硝基苯酚 可购自上海毕得医药有限公司
实施例1 2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-硝基苯(Ⅱ)的制备
Figure PCTCN2022108014-appb-000011
向1L反应瓶加入19.0g(0.11mol)化合物Ⅲ和190mlN,N-二甲基甲酰胺，搅拌分批加入4.4g(0.11mol)氢氧化钠，控温0-10℃，加毕搅拌0.5小时，滴加入溶有22.3g(0.1mol)化合物Ⅵ的N,N-二甲基甲酰胺溶液100ml，升温到75-85℃，反应6小时。取样检测化合物Ⅵ消耗完毕降温至室温，浓缩所得反应液，浓缩近干，加入200ml乙酸乙酯和200ml水，搅拌分液，乙酸乙酯层水洗两次，每次100ml，乙酸乙酯层减压浓缩至干。所得残余物加入乙醇重结晶，得到黄色固体31.2g，摩尔收率90％。
MS(m/z)：348(M+H)。
实施例2 2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-硝基苯(Ⅱ)的制备
Figure PCTCN2022108014-appb-000012
向500ml反应瓶加入19.0g(0.11mol)化合物Ⅲ和190ml丙酮，加入 20.7g(0.11mol)碳酸钾，加入22.3g(0.1mol)化合物Ⅵ，升温到55℃，回流反应8小时。取样检测化合物Ⅵ消耗完毕降温至室温，过滤所得反应液，浓缩干。所得残余物加入乙醇重结晶，过滤，干燥得到黄色固体30.5g，摩尔收率88％。
MS(m/z)：348(M+H)。
实施例3 2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺(Ⅰ)的制备
Figure PCTCN2022108014-appb-000013
向2L高压釜中加入34.7g(0.1mol)化合物Ⅱ2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-硝基苯和400ml四氢呋喃，搅拌加入0.45g(0.002mol)二氧化铂，氢气置换空气，加压至0.3MPa(3个大气压)，升温到45-55℃，反应4小时，观察无明显吸气现象，取样检测，化合物Ⅱ消耗完毕。降温至室温，过滤所得反应液，母液浓缩干，加200ml水，搅拌过滤，再以200ml水洗一次，真空烘干，得到棕色固体31.4g，摩尔收率95％。
MS(m/z)：331.12(M+H).1HNMR(400MHz,DMSO)δ:3.93(d,6H),5.42(s,2H),6.42(d,1H),6.91(d,1H),6.98-7.04(m,1H),7.20-7.21(m,1H),7.37(s,1H),7.48(s,1H),8.45(d,1H).
实施例4 2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺(Ⅰ)的制备
Figure PCTCN2022108014-appb-000014
向1L反应瓶中加34.7g(0.1mol)化合物Ⅱ2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-硝基苯和300ml乙醇，加入66.4g(0.35mol)氯化亚锡，搅拌升温至60℃，滴加67ml(0.8mol)浓盐酸，升到回流反应3小时，取样检测，化合物Ⅱ消耗完毕。降温，4N氢氧化钠溶液调节pH至9，过滤，所得反应液浓缩，水洗，真空烘干,得到褐色固体28.1g，摩尔收率85％。
MS(m/z)：331.12(M+H).1HNMR(400MHz,DMSO)δ:3.93(d,6H),5.42(s,2H),6.42(d,1H),6.91(d,1H),6.98-7.04(m,1H),7.20-7.21(m,1H),7.37(s,1H),7.48(s,1H),8.45(d,1H).
对比例1 2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺(Ⅰ)的制备
Figure PCTCN2022108014-appb-000015
250ml反应瓶中加入4.5g(31.4mmol)4-氨基-3-氯苯酚，二甲亚砜50ml，搅拌加入1.26g钠氢(60％)，控温10-25℃，搅拌0.5小时，加入5g(22.4mmol)化合物Ⅵ，搅拌升温至100℃，反应9小时，冷至15-20℃，将反应液倾入100ml冰水中，控温15-30℃，加入乙酸乙酯20ml，过滤所得混合物，固体再以10ml乙酸乙酯洗一次，真空烘干，得到5.18g化合物Ⅰ，摩尔收率70％。
对比例2 2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺(Ⅰ)的制备
Figure PCTCN2022108014-appb-000016
500ml反应瓶中加入22.4g(0.1mol)化合物Ⅵ，300mlN,N-二甲基甲酰胺，17.2g(0.12mol)4-氨基-3-氯苯酚，13.5g(0.12mol)叔丁醇钾，升温到120℃反应8小时，冷至室温，加500ml水，800ml*3二氯甲烷萃取，有机相用300ml*2水洗涤，再用盐水300ml洗涤。二氯甲烷干燥，柱层析纯化得到25.6g产物，收率77.6％。
对比例3 2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺(Ⅰ)的制备
Figure PCTCN2022108014-appb-000017
向250ml反应瓶中加入4.74g(0.033mol)4-氨基-3-氯苯酚和70ml二甲亚砜，再加入2.64g(0.066mol)钠氢，搅拌15分钟，加入6.71g(0.03mol)式Ⅵ化合物，升温到160℃搅拌2小时，冷至室温，加入200ml水，600ml乙酸乙酯萃取。有机相以600ml*3盐水洗涤，有机相无水硫酸钠干燥，减压旋蒸，柱层析纯化，得到4.8g，收率48％。
综上，本发明原料易得，成本低廉，反应条件温和，产品易纯化，且收率高，是适宜工业化大生产的制备化合物2-氯-4-((6，7-二甲氧基喹啉-4-基)氧)-苯胺的方法。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 一种式Ⅰ化合物的制备方法，其特征在于，包括步骤：
    Figure PCTCN2022108014-appb-100001
    s1)在惰性溶剂中，碱存在下，式Ⅲ化合物与式Ⅵ化合物发生反应，得到式Ⅱ化合物；所述反应的温度为40-80℃；
    s2)在惰性溶剂中，催化剂存在下，式Ⅱ化合物与还原剂反应，得到式Ⅰ化合物。
  2. 如权利要求1所述的方法，其特征在于，步骤s1)中，所述碱为无机碱，且所述碱选自：氢氧化钠、氢氧化钾、钠氢、氨基钠、碳酸钾、碳酸钠，或其组合，优选地为氢氧化钠、氢氧化钾、碳酸钾、碳酸钠，或其组合。
  3. 如权利要求1所述的方法，其特征在于，步骤s1)中，惰性溶剂选自：N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、丙酮、二甲亚砜、乙腈、四氢呋喃，或其组合。
  4. 如权利要求1所述的方法，其特征在于，步骤s1)中，所述反应的温度为60-80℃，较佳地，50-70℃。
  5. 如权利要求1所述的方法，其特征在于，步骤s2)中，所述催化剂选自下组：钯碳、雷尼镍、二氧化铂，还原剂为H 2。
  6. 如权利要求1所述的方法，其特征在于，步骤s2)中，还原剂为金属试剂，优选地为铁粉、锌粉、氯化亚锡。
  7. 如权利要求6所述的方法，其特征在于，步骤s2)中，催化试剂为酸性试剂，优选地为盐酸、醋酸、氯化铵水溶液。
  8. 如权利要求7所述的方法，其特征在于，步骤s2)中，所述酸性试剂和金属试剂的组合选自：盐酸和铁粉、盐酸和锌粉、醋酸和铁粉、氯化铵水溶液和铁粉、盐酸和氯化亚锡。
  9. 一种式Ⅱ化合物的制备方法，其特征在于，所述方法包括步骤：
    Figure PCTCN2022108014-appb-100002
    s1)在惰性溶剂中，碱存在下，式Ⅲ化合物与式Ⅵ化合物发生反应，得到式Ⅱ化合物。
  10. 一种式Ⅰ化合物的制备方法，其特征在于，所述方法包括步骤：
    Figure PCTCN2022108014-appb-100003
    s2)在惰性溶剂中，催化剂存在下，式Ⅱ化合物与还原剂反应，得到式Ⅰ化合物。
PCT/CN2022/108014 2022-01-17 2022-07-26 一种替沃扎尼关键中间体的制备方法 WO2023134145A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210050136.8 2022-01-17
CN202210050136.8A CN116478090A (zh) 2022-01-17 2022-01-17 一种替沃扎尼关键中间体的制备方法

Publications (1)

Publication Number Publication Date
WO2023134145A1 true WO2023134145A1 (zh) 2023-07-20

Family

ID=87218292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/108014 WO2023134145A1 (zh) 2022-01-17 2022-07-26 一种替沃扎尼关键中间体的制备方法

Country Status (2)

Country Link
CN (1) CN116478090A (zh)
WO (1) WO2023134145A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102532116A (zh) * 2011-08-09 2012-07-04 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN103420986A (zh) * 2012-05-18 2013-12-04 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
CN104072492A (zh) * 2013-11-27 2014-10-01 苏州摩尔医药有限公司 一种抗肿瘤靶向治疗药物Tivozanib的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102532116A (zh) * 2011-08-09 2012-07-04 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN103420986A (zh) * 2012-05-18 2013-12-04 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
CN104072492A (zh) * 2013-11-27 2014-10-01 苏州摩尔医药有限公司 一种抗肿瘤靶向治疗药物Tivozanib的合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WU, YUN ET AL.: "Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6, 7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors,", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 13, 17 June 2019 (2019-06-17), pages 6083 - 6101, XP055940696, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00280 *

Also Published As

Publication number Publication date
CN116478090A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
CN102295594B (zh) 4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用
EP3828170A1 (en) Method for safely preparing pimavanserin and tartrate salt thereof using triphosgene
CN102295638B (zh) 拉帕替尼的制备方法
CN100451015C (zh) 一种伊马替尼的制备方法
CN110950765B (zh) 一种硫酸特布他林的制备方法
CN109956870A (zh) 一种罗沙司他的合成方法及其中间体化合物
JP7038263B2 (ja) モルホリノキナゾリン化合物の製造方法及びその中間体
CN102584795A (zh) 一种克里唑替尼的制备方法
CN110511207A (zh) 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN108129513A (zh) 一种合成布格替尼中间体的方法
CN104860923A (zh) 富马酸沃诺拉赞的制备方法
CN101654419A (zh) 马来酸氟伏沙明的制备方法
CN103601645A (zh) 1-(苯乙基氨基)丙烷-2-醇类化合物或其盐的制备方法
CN105254559B (zh) 一种高纯度罗氟司特的制备方法
WO2023134145A1 (zh) 一种替沃扎尼关键中间体的制备方法
CN107118215A (zh) 一种治疗乳腺癌药物瑞博西尼中间体的制备方法
CN104744336B (zh) 一种西洛多辛中间体及其制备方法，以及用该中间体制备西洛多辛的方法
CN111100042B (zh) 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
CN105461640A (zh) 一种酪氨酸激酶抑制剂的制备方法
CN109651271A (zh) 一种3-叔丁基-n-甲基喹喔啉-2(1h)-酮化合物的合成方法
CN108558758A (zh) 一种4-氟异喹啉-5-胺的合成方法
CN113754606B (zh) 吩噁嗪二胺衍生物和/或吩噻嗪二胺衍生物及其制备方法
CN108409648B (zh) 一种甲苯磺酸索拉非尼相关中间体的制备方法
CN105566182A (zh) 一种2-氨基-4-（乙磺酰基）苯酚的合成方法
CN102993116A (zh) 一种苯并噁嗪类激动剂的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22919782

Country of ref document: EP

Kind code of ref document: A1